KEYNOTE: Next Generation for Cell Therapies

Carl June, University of Pennsylvania

EXECUTIVE PANEL: Exploring the hurdles that are in place whilst targeting solid tumors; and how to clear the route for an “off the shelf” therapy

MODERATOR: Nick Serseni, EY

Peter Emtage, Kite Pharma Inc

Pascal Touchon, Atara Biotherapeutics

Stefan Wildt, Takeda Pharmaceuticals

HEADLINE KEYNOTE: Unlocking the power of data and technology to deliver on the promise of cell and gene therapies

Aldai Goldberg, EY

David C. Rhew, Microsoft

Orlando Serani, Johnson & Johnson

Sarah Dye, Optum

CAR-T R&D - PRESENTATION: Cartitude-1 Study with Updates in Toxicity & Management

Deepu  Madduri, Mount Sinai Hospital

VEIN TO VEIN - PRESENTATION:Transitioning from outsourcing to in-house manufacturing facilities and accessing cell therapy manufacturing models

Knut Niss, Mustang


David Miklos, Stanford University

NATURAL KILLER CELLS -PRESENTATION: Natural Killer cells in cancer immunotherapy

Jeffrey Miller, University of Minnesota 

CAR-T R&D - PRESENTATION: Technology (and) Innovation to support the global scaleup challenges on the horizon

Steven Lynum,  PHC Corporation (Japan)

Carl Radosevich, PHC Corporation

CLINICAL & COMMERCIALIZATION -PRESENTATION: Non-viral technologies for development and manufacture of next generation cell therapies

Shirley O’Dea, Avectas

CAR-T R&D - PRESENTATION: Using Red Cell Therapeutics to Enhance Antitumor Immune Reponses

Chris Coughlin, Rubius Therapeutics

VEIN TO VEIN - PRESENTATION: Guidelines for cell characterisation and cell function

John T Elliot, NIST

CLINICAL & COMMERCIALIZATION - PRESENTATION: Large B cell lymphoma long term safety trials

Caron Jacobson, Dana Faber Cancer Institute

NATURAL KILL CELLS - PRESENTATION: Maximising the therapeutic effect of allogeneic natural killer cells

James Trager, Nkarta
Ivan Chan, Nkarta

PRESENTATION: Scale-Out of Commercially Viable Autologous CAR T Cell Manufacturing 

Fred Koller, Miltenyi Biotec

PRESENTATION: Development of autologous cellular immunotherapies optimizing personalized, tumor directer TILs 

Maria Fardis, Iovance Biotherapeutics

CAR-T R&D PRESENTATION: Enhancing CAR-T with small molecules to regulate for enhanced activity against solid tumor

Steve Shamah, Obsidian Therapeutics

VEIN TO VEIN PRESENTATION: CMC project management for cell and gene therapies

Moderator: Rachit Jain, Werum IT Solutions America

Seshu Tyagarajan, Novartis Pharmaceuticals

CLINICAL & COMMERCIALIZATION PRESENTATION: Development of TCR T cell Therapies for Treatment of Solid Tumors

Paul Stead, Adaptimmune

VEIN TO VEIN PRESENTATION: Next Generation Workforce Development for Cell Therapy Manufacturing

Haro Hartounian, BioPharma Innovation

CLINICAL & COMMERCIALIZATION PRESENTATION: Artificial intelligence for tumor specific neoantigen identification

Matt Davis, Gritstone Oncology

CAR-T R&D PRESENTATION: Molecular Characterization for CAR-T Cell Therapy:  A Step Toward Standardization with the nCounter® CAR-T Characterization Panel

Erin Piazza,NanoString Technologies

CLINICAL & COMMERCIALIZATION PRESENTATION: Lentiviral vectors: towards more cost-effective, scalable and regulatory-compliance processes.

Dr Juan Carlos Ramirez, VIVEbiotech

Interactive Focused Round Table 1: Cell homing to target solid tumors

Robert Koechl, King's College London

Interactive Focused Round Table 2: Development of functional lymphocytes from human pluripotent stem cells
Dan Kaufman, University of California

Interactive Focused Round Table 3: Targeting glioblastoma through the use of cell therapies

Andrew Speigel, Global Colon Cancer Association

PRESENTATION: Fusion Proteins to bridge CAR19 T cell and tumor cells

Paul Rennert,  Aleta Biotherapeutics Inc

PRESENTATION: Vd1 Gammadelta T Cells

Alice Brown, Gammadelta Therapeutics

PRESENTATION: Challenges of Vector Production in Support of Phase I Clinical Trials

Steven Feldman, Stanford University

PRESENTATION: Best practice REMS development

Larissa Lapteva, FDA

PRESENTATION: Adoptive cell therapy using engineered TAC T-cells to invade solid tumors

Paul Lammers, Triumvira

PRESENTATION: TRuC®-T Cells: Harnessing The Full T Cell Receptor without HLA Restriction for Cancer Therapy

Robert Hofmeister, TCR2 Therapeutics

PRESENTATION: Digital Solution for Cell and Gene Therapy with Lessons learned

Rachit Jain, Werum

Ryan Hamilton, Werum

PANEL: Allogeneic Therapies

Moderator: Peggy Sotiropoulou, Celyad Oncology

Alan Trounson, CEO, Cartherics